Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Bococizumab (USAN; development code RN316) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."
The analysis highlights Description, Clinical trials and Overview as prominent areas in the source structure around Bococizumab.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Explore different angles and find fresh ideas to shape your next piece of content.
Search suggestions related to this topic. Open a question to research it further; suggestions are not verified answers.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
You can skip this section if you’re here for content ideas and keyword inspiration.
The extracted context around Bococizumab shows recurring relationship patterns in the source. For example, Bococizumab → American College, Cardiology, LDL, LDL-C, Monthly, Pfizer, SPIRE, The Phase, Wide Another extracted example is Bococizumab → LDL, PCSK9. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
ldl development pfizer pcsk9 cholesterol drug code levels antibodies reduce patients trials antibody usan phase significantly anti-drug rn316 targeting withdrew
TTTA extracted 26 structured relationships around Bococizumab. Examples in this analysis include Bococizumab → ATC code → none and Bococizumab → CAS Number → 1407495-02-6. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Bococizumab | ATC code | none | 1.00 | infobox |
| Bococizumab | CAS Number | 1407495-02-6 | 1.00 | infobox |
| Bococizumab | ChEMBL | ChEMBL3137349 | 1.00 | infobox |
| Bococizumab | ChemSpider | none | 1.00 | infobox |
| Bococizumab | Formula | C6414H9918N1722O2012S54 | 1.00 | infobox |
| Bococizumab | IUPHAR/BPS | 7730 | 1.00 | infobox |
| Bococizumab | KEGG | D10621 Y | 1.00 | infobox |
| Bococizumab | Legal status | Investigational | 1.00 | infobox |
| Bococizumab | Molar mass | 145077.18 g·mol−1 | 1.00 | infobox |
| Bococizumab | PubChem SID | 194168554 | 1.00 | infobox |
| Bococizumab | Routes of administration | Subcutaneous injection | 1.00 | infobox |
| Bococizumab | Source | Humanized (from mouse) | 1.00 | infobox |
| Bococizumab | Target | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | 1.00 | infobox |
| Bococizumab | Type | Whole antibody | 1.00 | infobox |
| Bococizumab | UNII | 45M75JVK38 | 1.00 | infobox |
The concept neighborhoods around Bococizumab bring nearby vocabulary together. In this analysis, examples include Development, Ldl and Pfizer. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Bococizumab, one of the stronger structural bridges in this analysis connects Bococizumab with Overview. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Bococizumab to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Description, Clinical trials & Overview, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Bococizumab · EN edition · Analysis: TopicsToTalkAbout
